Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody

(2018) Gerd R. Burmester et al.   Arthritis & Rheumatology

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

(2017) John A. Hamilton et al.   NATURE REVIEWS DRUG DISCOVERY

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis

(2017) Xiang Guo et al.   RHEUMATOLOGY

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

(2016) Jacques-Eric Gottenberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation

(2016) Adrian Achuthan et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis

(2016) Helen L. Wright et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Least-Squares Means: TheRPackagelsmeans

(2016) Russell V. Lenth   Journal of Statistical Software

Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis

(2016) Ursula Fearon et al.   Nature Reviews Rheumatology

CXCL13 is a plasma biomarker of germinal center activity

(2016) Colin Havenar-Daughton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis

(2015) Onur Baser et al.   CLINICAL THERAPEUTICS

MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

(2014) Frank Behrens et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

(2014) P Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Cutting Edge: Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Inhibits Memory B Lymphocytes via Effects on Lymphoid Germinal Centers and Follicular Dendritic Cell Networks

(2014) J. H. Anolik et al.   JOURNAL OF IMMUNOLOGY

Involvement of the Circadian Rhythm and Inflammatory Cytokines in the Pathogenesis of Rheumatoid Arthritis

(2014) Kohsuke Yoshida et al.   Journal of Immunology Research

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor

(2013) Leslie R Harrold et al.   ANNALS OF THE RHEUMATIC DISEASES

Causal analysis approaches in Ingenuity Pathway Analysis

(2013) Andreas Krämer et al.   BIOINFORMATICS

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

(2012) P. Emery   RHEUMATOLOGY

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis

(2012) Luis Chara et al.   ARTHRITIS RESEARCH & THERAPY

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

(2011) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry

(2011) Daniel E. Furst et al.   ARTHRITIS CARE & RESEARCH

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

(2011) Der-Yuan Chen et al.   ARTHRITIS RESEARCH & THERAPY

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

(2009) Andrea Rubbert-Roth et al.   ARTHRITIS RESEARCH & THERAPY